Bhubaneswar, Nov. 24 -- The HSP Subunit Vaccine candidate, jointly developed by the Institute of Life Sciences (ILS), Bhubaneswar, and the Indian Institute of Technology (IIT) Bhubaneswar, marks a significant advancement in India's efforts to combat Mycobacterium tuberculosis.
The new vaccine candidate is engineered to elicit strong humoral and cell-mediated immune responses while boosting the protective efficacy of the existing BCG vaccine.
IIT Bhubaneswar and ILS Bhubaneswar, in partnership with the National Research Development Corporation (NRDC), have signed a Quadripartite License Agreement (QLA) with TechInvention Lifecare Limited for the technology transfer and future commercialization of the novel vaccine titled "HSP Subunit Vacci...